keyword
https://read.qxmd.com/read/34350269/narrative-review-of-theoretical-considerations-regarding-hithoc-between-past-and-future
#21
REVIEW
Tamas F Molnar, Andras Drozgyik
Hyppocrates constructed the medicines-surgery-energy triangle which includes all therapeutical modalities. Hyperthermic intraoperative chemotherapy (HITHOC) is a synergy-based single stage multimodality treatment encompassing the locoregional manifestation of the systemic malignant process. Pleural space, thermal effect, lavage/irrigation and chemotherapy represent the basic science ports of the network hub: HITHOC. The malignant transformation and process of the pleural surface (and underlying lung) challenges space management and tissue control...
June 2021: Annals of Translational Medicine
https://read.qxmd.com/read/34350267/present-and-future-of-hyperthermic-intrathoracic-chemotherapy-hithoc-in-thoracic-surgical-oncology
#22
EDITORIAL
Marcello Migliore
No abstract text is available yet for this article.
June 2021: Annals of Translational Medicine
https://read.qxmd.com/read/34346242/hyperthermic-intrathoracic-chemotherapy-in-thoracic-surgical-oncology-future-challenges-of-an-exciting-procedure
#23
EDITORIAL
Marcello Migliore, Tom Combellack, Jennifer Williams, Malgorzata Kornaszewska, Vasileios Valtzoglou, Ainis Pirtnieks
No abstract text is available yet for this article.
August 4, 2021: Future Oncology
https://read.qxmd.com/read/34298849/hyperthermic-intrathoracic-chemoperfusion-for-malignant-pleural-mesothelioma-systematic-review-and-meta-analysis
#24
REVIEW
Tommi Järvinen, Juuso Paajanen, Ilkka Ilonen, Jari Räsänen
Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Hyperthermic intrathoracic chemoperfusion (HITHOC) is commonly used with surgery in limited disease. However, data on its effect on survival are limited. In this systematic review and meta-analysis, we analyzed a total of 11 observational articles. HITHOC was compared to control arm that did not receive HITHOC in three studies including 762 patients. The pooled analysis of these studies revealed an SMD of 0...
July 20, 2021: Cancers
https://read.qxmd.com/read/34263367/cytoreductive-surgery-with-hyperthermic-intrathoracic-chemotherapy-for-patients-with-intrapleural-dissemination-of-peritoneal-surface-malignancies
#25
JOURNAL ARTICLE
Andrei Nikiforchin, Vadim Gushchin, Mary Caitlin King, Ekaterina Baron, Felipe Lopez-Ramirez, Armando Sardi
BACKGROUND: Peritoneal surface malignancies (PSM) can disseminate into the pleural cavity, increasing morbidity and mortality. While cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) improves outcomes for PSM with intra-abdominal spread, the optimal approach for patients with pleural dissemination from PSM remains unclear. It seems reasonable to apply peritoneal carcinomatosis management principles to patients with pleural lesions using CRS and hyperthermic intrathoracic chemotherapy (HITHOC)...
July 15, 2021: Annals of Surgical Oncology
https://read.qxmd.com/read/33506925/hyperthermic-intrathoracic-chemotherapy-combined-to-iterative-cytoreductive-surgery-to-treat-a-pleural-carcinosis-from-psudomixoma-peritonei-a-case-report
#26
JOURNAL ARTICLE
F Lococo, A Di Giorgio, A Iaffaldano, G Schinzari, D Tabacco, P Aceto, C Abatini, L Sollazzi, S Margaritora
Pseudomyxoma peritonei (PMP) is an uncommon disease with locally-invasive attitude. Intrathoracic spread is rarely reported and its management extremely challenging. A 51-year-old Caucasian female presented with left pleural carcinosis 9-months after two sequential abdominal surgical procedures combined with HIPEC for low-grade PMP. Cytoreductive surgery (pleurectomy/decortication) was followed by 60-minutes hyperthermic intrathoracic chemotherapy mitomycin-C (215 mg/m2) infusing at same temperature (42°C) and intrapleural pression (2-4 mmH2O)...
January 2021: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/32170942/surgical-treatment-of-pleural-recurrence-of-thymoma-is-hyperthermic-intrathoracic-chemotherapy-worthwhile
#27
JOURNAL ARTICLE
Vittorio Aprile, Diana Bacchin, Stylianos Korasidis, Agnese Nesti, Elena Marrama, Roberta Ricciardi, Iacopo Petrini, Marcello Carlo Ambrogi, Piero Paladini, Marco Lucchi
OBJECTIVES: Recurrence of thymoma is described in 10-30% of cases after surgical resection. Iterative surgery for thymoma pleural relapses (TPRs) is often part of a multimodal treatment. Hyperthermic intrathoracic chemotherapy (HITHOC) following macroscopic radical surgery is an option that combines the effects of mild hyperthermia with those of chemotherapeutic agents. We evaluated the effectiveness of surgery + HITHOC, compared with surgery alone, in the treatment of TPR. METHODS: We retrospectively collected data of all patients who underwent surgery for TPR in our centre from 2005 to 2017...
May 1, 2020: Interactive Cardiovascular and Thoracic Surgery
https://read.qxmd.com/read/31366459/does-cytoreduction-surgery-and-hyperthermic-intrathoracic-chemotherapy-prolong-survival-in-patients-with-n0-n1-nonsmall-cell-lung-cancer-and-malignant-pleural-effusion
#28
JOURNAL ARTICLE
Marcello Migliore, Marco Nardini
INTRODUCTION: Debulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) has been successfully used in the treatment of thoracic tumours. Few authors report on the feasibility of its use in patients with lung cancer and malignant pleural effusion. The aim of this study was to evaluate the efficacy and results of debulking surgery and HITHOC in the treatment of selected patients with nonsmall cell lung cancer (NSCLC) and malignant pleural effusion. METHODS: A systematic review was conducted in MEDLINE in accordance with PRISMA guidelines...
September 30, 2019: European Respiratory Review: An Official Journal of the European Respiratory Society
https://read.qxmd.com/read/31353039/perioperative-anesthetic-management-of-patients-with-malignant-pleural-mesothelioma-undergoing-cytoreductive-surgery-and-intraoperative-chemotherapy
#29
JOURNAL ARTICLE
J M Gómez Tarradas, G Pujol Fontrodona, M López-Baamonde, D Sánchez, M J Jiménez, R Navarro-Ripoll
INTRODUCTION: Cytoreductive surgery with hyperthermic intraoperative chemotherapy (HITHOC) is a therapeutic option for treatment of malignant pleural mesothelioma. Anesthetic management might be challenging. PATIENTS AND METHODS: A descriptive analysis of a case series is presented. Seven patients with malignant pleural mesothelioma diagnostic undergoing HITHOC surgery were studied. Combined general and epidural anesthesia were administered. An intensive hemodynamic monitorization was implemented...
January 2020: Revista española de anestesiología y reanimación
https://read.qxmd.com/read/31285889/pleurectomy-decortication-and-hyperthermic-intrathoracic-chemoperfusion-using-cisplatin-and-doxorubicin-for-malignant-pleural-mesothelioma
#30
JOURNAL ARTICLE
Laura V Klotz, Michael Lindner, Martin E Eichhorn, Uwe Grützner, Ina Koch, Hauke Winter, Teresa Kauke, Thomas Duell, Rudolf A Hatz
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with few long-term survivors. Despite the dismal prognosis, hyperthermic intrathoracic chemoperfusion (HITHOC) was shown to improve survival in a selective group of patients. We analyzed the influence of HITHOC following pleurectomy and decortication on postoperative morbidity and overall survival for patients suffering from localized mesothelioma. METHODS: From 2009 until 2013, 71 patients with localized pleural mesothelioma underwent pleurectomy and decortication followed by HITHOC with cisplatin and doxorubicin...
May 2019: Journal of Thoracic Disease
https://read.qxmd.com/read/31285871/clinical-factors-affecting-the-survival-of-patients-diagnosed-with-non-small-cell-lung-cancer-and-metastatic-malignant-pleural-effusion-treated-with-hyperthermic-intrathoracic-chemotherapy-or-chemical-talc-pleurodesis-a-monocentric-prospective-randomized-trial
#31
JOURNAL ARTICLE
Athanasios Kleontas, Antonia Sioga, Niki Pandria, Nikolaos Barbetakis, Achilleas Lazopoulos, Ioannis Katsikas, Christos Asteriou, Dimitrios Paliouras, Efstathios Kamperis, Dimitrios Ikonomou, Theodora Papamitsou, Dimitrios Filippou, Chariklia Destouni, Louiza Ikonomou, Konstantinos Zarogoulidis, Kostas Papagiannopoulos
BACKGROUND: There is a plethora of treatment algorithms for managing patients with malignant pleural effusions (MPEs), sharing many common points and principles. Our study aims to compare hyperthermic intrapleural chemotherapy (HITHOC) and talc pleurodesis (TALC), as treatment options for patients with non-small cell lung cancer (NSCLC) and metastatic MPE. METHODS: This prospective, randomized trial was conducted at a single thoracic surgery center, the "Theagenio" Cancer Institute, in Greece, under the identification code NCT01409551 and was completed...
May 2019: Journal of Thoracic Disease
https://read.qxmd.com/read/30886500/hyperthermic-intrathoracic-chemotherapy-hithoc-for-pleural-malignancies-experience-from-indian-centers
#32
JOURNAL ARTICLE
Mahesh D Patel, Dileep Damodaran, Ashvin Rangole, Sakina Shaikh, Kairav Shah, Rajendra Bagwade, Aditi Bhatt
Hyperthermic intrathoracic chemotherapy (HITHOC) has been used in addition to radical surgery for primary and secondary pleural malignancies to improve local control, prolong survival, and improve the quality of life. This study was performed to study the indications, methodology, perioperative outcomes, and survival in patients undergoing HITHOC at Indian centers. A retrospective analysis of prospectively collected demographic and clinical data, perioperative and survival data of patients undergoing surgery with or without HITHOC was performed...
February 2019: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/30722125/hyperthermic-intrathoracic-chemotherapy-hithoc-in-ovarian-carcinoma-a-propos-of-a-case
#33
JOURNAL ARTICLE
Dejan Stojiljkovic, Srdjan Nikolic, Ana Cvetkovic, Vladimir Jokic, Igor Spurnic, Stevan Jokic, Merima Goran, Milan Kocic, Nebojsa Miletic, Jovan Filipovic, Tanja Stojiljkovic, Branislav Lukac
A female patient aged 42, started chemotherapy for advanced ovarian carcinoma in June 2016. Considering intraoperative findings, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) were performed, followed by adjuvant chemotherapy. In March 2018, computed tomography (CT) examination showed disease progression in the form of pleural carcinomatosis with increased levels of tumor markers. In April 2018, total parietal pleurectomy, partial visceral pleurectomy, and then hyperthermic intrathoracic chemotherapy (HITHOC) with cisplatin were performed...
December 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://read.qxmd.com/read/29529693/-implementation-of-hyperthermic-intrathoracic-chemotherapy-hithoc-in-germany
#34
JOURNAL ARTICLE
Michael Ried, Hans-Stefan Hofmann, Hendrik Dienemann, Martin Eichhorn
INTRODUCTION: For several years, hyperthermic intrathoracic chemotherapy (HITHOC) has been performed in a few departments for thoracic surgery in a multimodality treatment regime in addition to surgical cytoreduction. Specific data about HITHOC in Germany are still lacking. METHODS: Survey in written form to all departments of thoracic surgery in Germany. The objective is the evaluation of HITHOC with respect to number, indications, technique, perioperative protection measure and complications...
June 2018: Zentralblatt Für Chirurgie
https://read.qxmd.com/read/29507790/hyperthermic-intrathoracic-chemotherapy-after-extended-pleurectomy-and-decortication-for-malignant-pleura-mesothelioma-an-observational-study-on-outcome-and-microcirculatory-changes
#35
JOURNAL ARTICLE
Luca Luzzi, Federico Franchi, Annarita Dapoto, Marco Ghisalberti, Roberto Corzani, Daniele Marrelli, Luca Marchetti, Piero Paladini, Sabino Scolletta
Background: In the treatment of malignant pleural mesothelioma the Hyperthermic Intra THOracic Chemotherapy (HITHOC) can improve the efficacy of pleurectomy and decortication with a local cytotoxic effect. However its biological impact in patient's hemodynamic and microcirculatory changes were rarely investigated. Aim of this study is to describe our experience with HITHOC after pleurectomy and decortication evaluating the role of sublingual video-microscopy in assessing the microcirculatory changes in the perioperative period...
January 2018: Journal of Thoracic Disease
https://read.qxmd.com/read/29353975/debulking-surgery-and-hyperthermic-intrathoracic-chemotherapy-hithoc-for-lung-cancer
#36
JOURNAL ARTICLE
Marcello Migliore
No abstract text is available yet for this article.
December 2017: Chinese Journal of Cancer Research
https://read.qxmd.com/read/29246008/effect-of-hyperthermic-intrathoracic-chemotherapy-on-the-malignant-pleural-mesothelioma-a-systematic-review-and-meta-analysis
#37
JOURNAL ARTICLE
Zi-Yi Zhao, Sha-Sha Zhao, Meng Ren, Zi-Ling Liu, Zhi Li, Lei Yang
Surgery-based multimodality therapies have been used to control the malignant effusion and its recurrence in malignant pleural mesothelioma (MPM). Hyperthermic intrathoracic chemotherapy (HITHOC) has been used in the treatment of malignant pleural mesothelioma, but the results were controversial. The aim of the current study was, therefore, to conduct a systematic review and meta-analysis on the effect of HITHOC on MPM therapy. After thorough searching of online databases, total 21 articles were included into qualitative systematic review and 5 of them were used to conduct qualitative meta-analysis...
November 21, 2017: Oncotarget
https://read.qxmd.com/read/29191688/diaphragm-and-lung-preserving-surgery-with-hyperthermic-chemotherapy-for-malignant-pleural-mesothelioma-a-10-year-experience
#38
COMMENT
Marcello Carlo Ambrogi, Pietro Bertoglio, Vittorio Aprile, Antonio Chella, Stylianos Korasidis, Gabriella Fontanini, Olivia Fanucchi, Marco Lucchi, Alfredo Mussi
BACKGROUND: The best surgical treatment for malignant pleural mesothelioma is still under a debate, but recent evidence points toward a less-invasive approach to reduce morbidity and mortality. We reported our 10-year experience of a limited surgical approach associated with hyperthermic intrathoracic chemotherapy (HITHOC). MATERIAL AND METHODS: Between 2005 and 2014, patients with epithelioid or biphasic malignant pleural mesothelioma were treated with lung-diaphragm-pericardium-sparing pleurectomy associated with double-drug HITHOC; at least 3 cycles of adjuvant chemotherapy were then administered...
April 2018: Journal of Thoracic and Cardiovascular Surgery
https://read.qxmd.com/read/28072694/effect-of-hyperthermic-intrathoracic-chemotherapy-hithoc-on-the-malignant-pleural-effusion-a-systematic-review-and-meta-analysis
#39
REVIEW
Hua Zhou, Wei Wu, Xiaoping Tang, Jianying Zhou, Yihong Shen
BACKGROUND: Although hyperthermic intraperitoneal chemotherapy (HIPEC) has been widely used to treat malignant ascites or as a preventive strategy for microscopic carcinomatosis following surgical resection of abdominal tumors, application of hyperthermic intrathoracic chemotherapy (HITHOC) in the treatment of malignant pleural effusion is limited. The objective of the current study was to conduct a systematic review and meta-analysis on the application of HITHOC in the palliative treatment of malignant pleural effusion...
January 2017: Medicine (Baltimore)
https://read.qxmd.com/read/26638918/pleurectomy-decortication-and-hyperthermic-intrapleural-chemotherapy-for-malignant-pleural-mesothelioma-initial-experience
#40
JOURNAL ARTICLE
Marcello Migliore, Damiano Calvo, Alessandra Criscione, Stefano Palmucci, Giovanni Fuccio Sanzà, Rosario Caltabiano, Corrado Spatola, Giuseppe Privitera, Marco Maria Aiello, Hector Soto Parra, Nicola Ciancio, Giuseppe Di Maria
Cytoreductive surgery and hyperthermic intraoperative intrapleural chemotherapy (HITHOC) are a known option for malignant pleural mesothelioma (MPM). This prospective study was started to prove that pleurectomy/decortication and HITHOC could be successfully performed in a low volume center. Criteria of inclusion were a proven diagnosis of MPM, early-stage disease and good performance status. Six consecutive patients were enrolled. After pleurectomy/decortication, intrapleural cisplatin was administered for 60 min at 42...
2015: Future Oncology
keyword
keyword
64732
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.